Cite
LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion.
MLA
Xiang, Yu, et al. “LMP2-MRNA Lipid Nanoparticle Sensitizes EBV-Related Tumors to Anti-PD-1 Therapy by Reversing T Cell Exhaustion.” Journal of Nanobiotechnology, vol. 21, no. 1, Sept. 2023, p. 324. EBSCOhost, https://doi.org/10.1186/s12951-023-02069-w.
APA
Xiang, Y., Tian, M., Huang, J., Li, Y., Li, G., Li, X., Jiang, Z., Song, X., & Ma, X. (2023). LMP2-mRNA lipid nanoparticle sensitizes EBV-related tumors to anti-PD-1 therapy by reversing T cell exhaustion. Journal of Nanobiotechnology, 21(1), 324. https://doi.org/10.1186/s12951-023-02069-w
Chicago
Xiang, Yu, Miaomiao Tian, Juan Huang, Yueyi Li, Guangqi Li, Xue Li, Zedong Jiang, Xiangrong Song, and Xuelei Ma. 2023. “LMP2-MRNA Lipid Nanoparticle Sensitizes EBV-Related Tumors to Anti-PD-1 Therapy by Reversing T Cell Exhaustion.” Journal of Nanobiotechnology 21 (1): 324. doi:10.1186/s12951-023-02069-w.